Author: Dr. Ahmed Zayed, MD
Reviewed: [pending physician sign-off]
Word count: ~2100
Track: ZayedMD canonical
Status: Draft 1, Gemini-drafted with PubMed evidence (daily pipeline 2026-05-30)
News anchor: https://www.statnews.com/2026/05/28/fda-wellness-guidance-unvetted-blood-pressure-tech-floods-market/
Focus keyphrase: cuffless blood pressure devices
Hypertension management can be complex and frustrating on the best of days. Did you know that millions of people struggle to keep their blood pressure under control despite strict medication adherence? It is an ongoing battle for both the patient and the physician. Recently, you have likely noticed a new trend in your waiting room. Patients are arriving at the clinic with months of continuous data from their new smartwatches. It can be difficult to manage this sudden flood of unvetted numbers. If you are seeing patients presenting with detailed graphs from consumer wearables, you are not alone.
The FDA has recently relaxed its oversight on certain wellness wearables. This shift has opened the floodgates for new consumer tech. Major players such as Oura and Apple are entering the space with incredible speed. However, clinical validation remains incredibly inconsistent. The relaxation of FDA oversight means that you must now do the heavy lifting. You have to differentiate between a consumer wellness gadget and a strictly validated clinical tool for your patients. In this blog post, we will discuss what cuffless blood pressure devices are, how the FDA changes affect your practice, and how you can safely incorporate this new technology into patient care.
What are cuffless blood pressure devices?
Let’s take a look at the technology itself. For decades, the standard of care for measuring blood pressure has relied on the traditional inflatable cuff. Whether manual or automated, this occlusive method is an essential part of clinical practice. It physically compresses the artery to determine systolic and diastolic pressures.
However, cuffless blood pressure devices are changing the field entirely. These new tools measure blood pressure without occluding the artery at all. They come in many consumer-friendly forms such as smartwatches, fitness bands, and smart rings. Patients naturally love the convenience. They do not have to stop what they are doing to inflate a restrictive cuff on their arm multiple times a day.
Yes, the appeal of a simple ring is undeniable. What’s more, these devices promise continuous monitoring over 24 hours without interrupting sleep or daily tasks.
However, the underlying mechanisms are entirely different from traditional sphygmomanometers. Cuffless blood pressure measurement relies heavily on optical sensors and complex software algorithms. They do not measure pressure directly. Instead, they estimate the pressure based on secondary physiological signals in the body. (Schutte AE et al, Nature reviews. Cardiology 2022). They track the volume of blood moving through the tiny vessels in the skin.
Then, the software steps in to guess what the actual central blood pressure must be. This is where the clinical complexity begins. If you are going to adjust a patient’s medication dose, you need to know exactly how reliable that guess really is.
The FDA shift toward wellness wearables
The regulatory environment is shifting rapidly right now. Recently, the FDA relaxed oversight on certain wellness wearables. This new guidance essentially separates consumer wellness products from formal medical diagnostic devices.
If a manufacturer markets a device strictly for general wellness, it can often bypass rigorous premarket review. They do not claim to diagnose or treat a specific disease like clinical hypertension. Because of this loophole, the market is now flooded with unvetted tech. Tech companies can release devices that track cardiovascular metrics and estimate blood pressure without proving their absolute clinical accuracy to federal regulators.
They are classified simply as wellness gadgets. This creates a massive burden for your daily practice.
Your patients will inevitably bring these readings to their appointments. They will see a high number on their wrist and ask you to adjust their antihypertensive medications immediately. That is a dangerous move. You have to take the time to explain the difference between a fun consumer gadget and a validated clinical tool.
A wellness device might provide some interesting health trends over a long period. However, it cannot replace standard clinical measurements for diagnosing a serious condition. There is no exaggeration in saying that this lack of oversight creates a confusing gray area. You need to protect your patients from making abrupt medical decisions based on unverified algorithms.
How do photoplethysmography and AI algorithms work?
If you’re wondering how a simple plastic ring can guess a blood pressure reading, you need to look at the sensors. Most of these new devices utilize photoplethysmography. This technology shines a tiny light into the skin and measures the changes in light absorption as blood flows through the capillary beds.
It is the exact same basic technology used in a standard pulse oximeter. However, estimating blood pressure from this specific signal is much harder than simply measuring oxygen saturation. Many modern devices also track pulse transit time. This is the amount of time it takes for a single pulse wave to travel from the heart to a peripheral site such as the wrist or the finger. (Bradley CK et al, American journal of hypertension 2022).
The relationship between pulse transit time and blood pressure is not perfectly linear. It changes constantly based on arterial stiffness, age, hydration status, and other physiological factors. Your blood vessels are dynamic tubes. This is where artificial intelligence comes into play.
The AI models are trained on massive datasets to find hidden correlations between the optical signals and actual blood pressure. They use machine learning to bridge the physiological gap.
However, these algorithms are proprietary black boxes. You do not get to see how the software weights different variables for your specific patient. Besides this, the software is frequently updated over the air by the manufacturer. An algorithm that was moderately accurate in March might perform entirely differently in August after an automatic firmware update. This software instability makes it very hard to rely on the data for long-term clinical decisions.
Clinical validation challenges and accuracy gaps
Clinical validation remains incredibly inconsistent across the entire consumer technology industry. Some devices show great promise in tightly controlled laboratory settings. However, those same devices often fail miserably in real-world scenarios. We are looking at a massive spectrum of quality and reliability.
The lack of standardized testing
Traditional blood pressure monitors have established international standards for validation. Cuffless blood pressure devices do not easily fit into these old testing protocols. The European Society of Hypertension has clearly noted that traditional validation protocols are inadequate for cuffless technologies. The old rules do not account for the initial calibration process or the way algorithmic tracking degrades over time. (Stergiou GS et al, Journal of hypertension 2023).
Without a unified testing standard, manufacturers invent their own validation protocols. They test their devices on small groups of young, healthy populations and report highly favorable results. They rarely test them on older patients with stiff arteries, arrhythmias, or severe cardiovascular disease.
Real-world accuracy limitations
When independent medical researchers evaluate the accuracy of these devices, the results are often disappointing. The AI algorithms vary wildly in accuracy when applied to diverse real-world patient populations. (Mukkamala R et al, Hypertension 2021).
A device might track changes in blood pressure during a static sitting position perfectly in a lab. However, if the patient exercises, drinks coffee, or experiences a sudden emotional stressor, the accuracy drops significantly. The algorithms simply struggle to track dynamic physiological changes reliably. (Mukkamala R et al, Hypertension 2025).
This means the numbers your patients show you might be entirely fictional during periods of high physical stress. That is exactly when accurate readings matter most for preventing cardiovascular events.
The problem with device calibration
Most of these wearables cannot function entirely on their own out of the box. They require periodic calibration using a traditional upper-arm blood pressure cuff. This creates a massive point of failure for the entire system.
The AI algorithm needs a starting point to anchor its calculations. The patient must take a reading with a standard cuff and manually enter that number into the smartwatch application. The software then uses that baseline to interpret all future optical signals.
If the patient performs this initial calibration incorrectly, the device is doomed. If they use a poorly fitting cuff, sit in the wrong posture, or enter an inaccurate number, every single subsequent reading on the smartwatch will be systematically skewed. The algorithm will learn the wrong baseline and confidently display incorrect data for weeks.
Moreover, this calibration drifts over time. The physiological relationship between the optical signal and the actual blood pressure changes as the patient’s vascular tone shifts. Therefore, patients must recalibrate the device frequently to maintain any semblance of accuracy. (Bhatt BJ et al, European heart journal. Digital health 2025).
Many patients simply forget to do this. They rely on an outdated calibration value for months. When they bring you their phone showing a perfect history of normal blood pressure, you have no way to verify when the device was last properly calibrated against a medical-grade tool.
How is cuffless continuous monitoring tested?
Continuous 24-hour monitoring is the holy grail of hypertension management. Traditional ambulatory blood pressure monitoring provides excellent data, but it is deeply uncomfortable. It disrupts sleep and causes bruising. Patients generally hate wearing the inflating cuff for a full day.
A consumer-grade wearable promises the exact same 24-hour data without any of the physical discomfort. Let’s look at the actual clinical evidence. Recent large-scale validation studies of smartwatches show that cuffless measurement can indeed track broad trends over time for many users. (Liu ZD et al, IEEE journal of biomedical and health informatics 2023).
Yes, the sheer volume of data is impressive. A smartwatch can generate hundreds of individual readings per day without the patient even noticing.
However, validating a consumer-grade cuffless blood pressure device for actual continuous medical monitoring is exceptionally difficult. The device must remain perfectly accurate through changes in posture, arm position, and ambient temperature during sleep. Most consumer wearables fail to capture the crucial nocturnal dipping pattern accurately.
Optical sensors rely on stable capillary blood flow. When a patient rolls over in bed and compresses their arm, the optical signal degrades immediately. Independent clinical validation of these continuous monitoring devices is still in its infancy. (Hu JR et al, Cardiovascular digital health journal 2023). You cannot replace a prescribed clinical ambulatory monitor with a consumer wellness ring just yet.
What are the risks of relying on unvetted tech?
When your patients rely entirely on wellness gadgets for their cardiovascular health, they expose themselves to significant risks. You have to anticipate these problems before they happen in your practice.
The first major risk is false alarms. If an uncalibrated device suddenly shows a systolic reading of 190 while the patient is sitting on their couch, panic sets in immediately. The patient might rush to the emergency room in fear of an impending stroke. They endure hours of waiting, expensive tests, and massive anxiety. When the triage nurse finally checks them with a traditional hospital cuff, their blood pressure is completely normal.
False positives waste critical medical resources and cause severe distress.
In some cases, false reassurance is even more dangerous. A poorly performing algorithm might continually estimate a healthy blood pressure of 120/80 because it defaults to its baseline calibration. Meanwhile, the patient’s actual arterial pressure is climbing to dangerous levels. The device masks a silent hypertensive crisis.
The patient delays seeking essential medical care because their smartwatch tells them everything is perfectly fine. You must educate your patients about these specific dangers. They need to understand that the sensor on their wrist is making an educated guess, not a definitive medical diagnosis.
The role of consumer tech in hypertension management
You might think these devices are completely useless for medical professionals. That is the wrong move. They do have a very valid place in an all-rounded approach to your patient’s health.
Cuffless blood pressure devices in clinical practice present both distinct challenges and unique opportunities. (Henry B et al, Blood pressure 2024). While they are not diagnostic tools, they are excellent instruments for patient engagement.
When patients see their estimated blood pressure rising after a high-sodium meal or a particularly stressful day at the office, they start to pay attention. The immediate visual feedback on their smartphone promotes better lifestyle choices. They might start exercising more frequently, cooking better meals, and actually remembering to take their prescribed medications on time.
These devices can also alert you to broad, long-term trends. If a patient’s wearable shows a steady, undeniable upward trend over three months, it might prompt you to schedule an official clinical evaluation sooner than planned. The wearable acts as an early warning system.
You must actively guide your patients on how to use this new data. Tell them to focus on the long-term trends rather than obsessing over single, isolated readings. An anomalous spike on a Tuesday afternoon is not a medical emergency unless it is accompanied by actual physical symptoms such as chest pain or dizziness.
Is this technology ready for everyday clinical practice?
If you’re wondering what to tell your patients today, the answer is extreme caution. A recent international narrative review on cuffless blood pressure measurement devices makes it very clear that we are not quite ready for widespread clinical adoption. (Yang E et al, JAMA cardiology 2025).
The technology certainly shows incredible promise for the near future. We will eventually have highly accurate, continuous monitors that fit comfortably on a finger and meet all clinical standards. Right now, the accuracy gaps are simply too wide for comfort.
You should continue to encourage your patients to use traditional, validated upper-arm cuffs for their routine home monitoring. These traditional devices are proven to reduce cardiovascular events when used correctly. They remain the gold standard.
If a patient insists on using their new smartwatch, ask them to bring it to the clinic. You can check the wearable’s reading directly against your standard clinic sphygmomanometer in real time. This simple step gives you a sense of how far off the algorithm is for that specific patient. It is an essential step to ensure their safety and build trust.
Conclusion
Undoubtedly, managing hypertension is becoming more complicated with the rapid rise of consumer health technology. The sudden flood of new cuffless blood pressure devices can be overwhelming for both busy clinicians and anxious patients.
Major tech companies are marketing these wearables heavily to the public. You will continue to see more of this unvetted data in your practice every single week. While these gadgets are wonderful for general engagement and lifestyle motivation, they are not yet a safe substitute for validated medical equipment. You must remain the expert guide for your patients.
By understanding the physiological limitations of photoplethysmography and the flaws in AI algorithms, you can safely direct your patients toward better health. You can protect them from unnecessary emergency room visits and incorrect medication adjustments. If you maintain clear, honest communication about the critical difference between wellness tech and true medical tools, you can rest assured that your patients will receive the best possible care.
References
- Mukkamala R et al. Cuffless Blood Pressure Measurement: Where Do We Actually Stand?. Hypertension (Dallas, Tex. : 1979) 2025. doi:10.1161/HYPERTENSIONAHA.125.24822 (PMID: 40231350)
- Stergiou GS et al. European Society of Hypertension recommendations for the validation of cuffless blood pressure measuring devices: European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. Journal of hypertension 2023. doi:10.1097/HJH.0000000000003483 (PMID: 37303198)
- Schutte AE et al. Blood pressure and its variability: classic and novel measurement techniques. Nature reviews. Cardiology 2022. doi:10.1038/s41569-022-00690-0 (PMID: 35440738)
- Bradley CK et al. Cuffless Blood Pressure Devices. American journal of hypertension 2022. doi:10.1093/ajh/hpac017 (PMID: 35136906)
- Yang E et al. Cuffless Blood Pressure Measurement Devices-International Perspectives on Accuracy and Clinical Use: A Narrative Review. JAMA cardiology 2025. doi:10.1001/jamacardio.2025.0662 (PMID: 40266607)
- Mukkamala R et al. Evaluation of the Accuracy of Cuffless Blood Pressure Measurement Devices: Challenges and Proposals. Hypertension (Dallas, Tex. : 1979) 2021. doi:10.1161/HYPERTENSIONAHA.121.17747 (PMID: 34510915)
- Liu ZD et al. Cuffless Blood Pressure Measurement Using Smartwatches: A Large-Scale Validation Study. IEEE journal of biomedical and health informatics 2023. doi:10.1109/JBHI.2023.3278168 (PMID: 37204948)
- Bhatt BJ et al. Validation of a popular consumer-grade cuffless blood pressure device for continuous 24 h monitoring. European heart journal. Digital health 2025. doi:10.1093/ehjdh/ztaf044 (PMID: 40703116)
- Henry B et al. Cuffless Blood Pressure in clinical practice: challenges, opportunities and current limits. Blood pressure 2024. doi:10.1080/08037051.2024.2304190 (PMID: 38245864)
- Hu JR et al. Validating cuffless continuous blood pressure monitoring devices. Cardiovascular digital health journal 2023. doi:10.1016/j.cvdhj.2023.01.001 (PMID: 36865583)
- https://www.statnews.com/2026/05/28/fda-wellness-guidance-unvetted-blood-pressure-tech-floods-market/
Licensed physician and clinical AI specialist. Founder and Editor-in-Chief of ZayedMD, a physician-led medical publication covering clinical AI, neurology, metabolic health, and evidence-based patient guidance.
